Feedback inhibition of gonadotropins by testosterone in men with hypogonadotropic hypogonadism: Comparison to the intact pituitary-testicular axis in primary hypogonadism

Journal of Andrology

Volumn 27, Issue 3, 2006, Pages 358-364

  Shimon, Ilan ^a,b   Lubina, Alexandra ^b,c   Gorfine, Malka ^d   Ilany, Jacob ^b,c  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d BAR ILAN UNIVERSITY   (Israel)

Author keywords

Androgen replacement; FSH; LH

Indexed keywords

FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; TESTOSTERONE; TESTOSTERONE ENANTATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; HYPOPHYSIS TESTIS SYSTEM; MALE; NEGATIVE FEEDBACK; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; FEEDBACK, BIOCHEMICAL; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGONADISM; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PITUITARY GLAND; TESTIS; TESTOSTERONE;

EID: 33646349747     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.05140     Document Type: Article

References (12)

1. Darby E, Anawalt BD. Male hypogonadism: an update on diagnosis and treatment. Treat Endocrinol. 2005;4:293-309.
2. Drincic A, Arseven OK, Sosa E, Mercado M, Kopp P, Molitch ME. Men with acquired hypogonadotrophic hypogonadism treated with testosterone may be fertile. Pituitary. 2003;6:5-10.
3. Hayes FJ, Seminara SB, Crowley WF Jr. Hypogonadotrophic hypogonadism. Endocrinol Metab Clin North Am. 1998;27:739-763.
4. Matsumoto AM. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab. 1990;70:282-287.
5. Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am. 1994;23:857-875.
6. Morales A. Androgen replacement therapy and prostate safety. Eur Urology. 2002;41:113-120.
7. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-492.
8. Salehian B, Wang C, Alexander G, Davidson T, McDonald V, Berman N, Dudley RE, Ziel F, Swerdloff RS. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate - a clinical research center study. J Clin Endocrinol Metab. 1995;80:3567-3575.
9. Sheckter CB, Matsumoto AM, Bremner WJ. Testosterone administration inhibits gonadotropin secretion by an effect directly on the human pituitary. J Clin Endocrinol Metab. 1989;68:397-401.
10. Shimon I, Cohen O, Lubetsky A, Olchovsky D. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid. 2002;12:823-827.
11. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85:4500-4510.
12. Tenover JL. Male hormone replacement therapy including "andropause." Endocrinol Metab Clin North Am. 1998;27:969-987.